Dr Reddy’s Laboratories has entered into an agreement to acquire a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications in the US.
The portfolio includes more than 30 generic injectable products which will require to be technology transferred and could be launched in one or two years. The value of total addressable market in 2018 for these products in the US was about $645 million, said a release.
“The acquisition is in line with our strategy to enhance our portfolio in our growth markets,’’ said Dr Reddy’s Labs COO Erez Israeli.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.